Assembly Biosciences
ASMB
109 hedge funds and large institutions have $163M invested in Assembly Biosciences in 2020 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 39 increasing their positions, 25 reducing their positions, and 37 closing their positions.
271% more call options, than puts
Call options by funds: $749K | Put options by funds: $202K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
56% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 25
0.9% less ownership
Funds ownership: 7.75% → 6.84% (-0.9%)
8% less funds holding
Funds holding: 118 → 109 (-9)
24% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 37
67% less capital invested
Capital invested by funds: $502M → $163M (-$339M)
Top Buyers
Top Sellers
ASMB Hedge Fund Activity: Q4 2020 in Review
109 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Assembly Biosciences (ASMB) for Q4 2020, worth a combined $163M — down 67% from $502M a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of ASMB and 28 opened new positions — a net loss of 9 holders — while 25 trimmed existing stakes and 39 added.
The largest buyer was Armistice Capital, adding an estimated $18.1M. The largest seller was Jennison Associates, exiting entirely with an estimated $38.8M sold.
- 109 institutional investors held Assembly Biosciences (ASMB) as of Q4 2020, down from 118 in Q3 2020.
- Funds reported $163M of Assembly Biosciences stock for Q4 2020, down 67% quarter-over-quarter.
- 28 funds opened new Assembly Biosciences positions in Q4 2020 and 37 closed out, a net change of -9 holders.
- The largest Assembly Biosciences buyer in Q4 2020 was Armistice Capital, an estimated $18.1M added.
- The largest Assembly Biosciences seller in Q4 2020 was Jennison Associates, an estimated $38.8M sold.
Based on aggregated 13F filings for Q4 2020.